Current status and thinking of small-molecule drug discovery for the treatment of COVID-19
10.13220/j.cnki.jipr.2020.07.006
- VernacularTitle: 治疗新冠肺炎小分子药物研发国际现状和思考
- Author:
Zhi-Fei LI
1
Author Information
1. China National Center for Biotechnology Development
- Publication Type:Journal Article
- Keywords:
Clinical research;
COVID-19;
Research and development status;
Small-molecule drug
- From:
Journal of International Pharmaceutical Research
2020;47(7):522-528
- CountryChina
- Language:Chinese
-
Abstract:
The discovery of small-molecule drugs for the treatment of COVID-19 is one of the most concerned research fields in drug discovery. Different kinds of small-molecule drugs approved or being developed are currently under clinical studies for the treatment of COVID-19. At present, the design of most clinical trials for the treatment of COVID-19 is lack of rationality. Moreover, the efficacy of drugs is controversial. High-quality results of clinical research are urgently needed. There is no small-molecule drugs in clinical studies that have specific effects on SARS-CoV-2. To find more drug candidates, artificial intelligence, structure-based drug design and other methods are applied to discover pre-clinical small molecule compounds against important protein targets of SARS-CoV-2 and virus host. Resources should be further integrated to discover drugs with specific effects to treat COVID-19.
